CN1330299C - 一种治疗颅外实体肿瘤的药物组合物 - Google Patents
一种治疗颅外实体肿瘤的药物组合物 Download PDFInfo
- Publication number
- CN1330299C CN1330299C CNB2005100434800A CN200510043480A CN1330299C CN 1330299 C CN1330299 C CN 1330299C CN B2005100434800 A CNB2005100434800 A CN B2005100434800A CN 200510043480 A CN200510043480 A CN 200510043480A CN 1330299 C CN1330299 C CN 1330299C
- Authority
- CN
- China
- Prior art keywords
- cancers
- tumor
- carmustine
- carcinoma
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 129
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title abstract description 20
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims abstract description 151
- 229960005243 carmustine Drugs 0.000 claims abstract description 142
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 230000001093 anti-cancer Effects 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 5
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 61
- 239000007943 implant Substances 0.000 claims description 59
- 229920001577 copolymer Polymers 0.000 claims description 41
- 229920000954 Polyglycolide Polymers 0.000 claims description 33
- 239000004633 polyglycolic acid Substances 0.000 claims description 33
- 229960004275 glycolic acid Drugs 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 238000013268 sustained release Methods 0.000 claims description 22
- 239000012730 sustained-release form Substances 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 201000001514 prostate carcinoma Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000010174 renal carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 22
- 229920000642 polymer Polymers 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 208000014018 liver neoplasm Diseases 0.000 abstract description 5
- 208000020816 lung neoplasm Diseases 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 231100000057 systemic toxicity Toxicity 0.000 abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 38
- 239000007924 injection Substances 0.000 description 38
- 239000004626 polylactic acid Substances 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 30
- 239000000546 pharmaceutical excipient Substances 0.000 description 29
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 28
- 229950004403 polifeprosan Drugs 0.000 description 28
- 229920000747 poly(lactic acid) Polymers 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000002513 implantation Methods 0.000 description 16
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000005038 ethylene vinyl acetate Substances 0.000 description 10
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 229920002732 Polyanhydride Polymers 0.000 description 8
- 230000003217 anti-cancerogenic effect Effects 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000002131 composite material Substances 0.000 description 7
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 230000005760 tumorsuppression Effects 0.000 description 5
- 229920002101 Chitin Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229920005576 aliphatic polyanhydride Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229920002627 poly(phosphazenes) Polymers 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920001273 Polyhydroxy acid Polymers 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- -1 chrondroitin Polymers 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001558 organosilicon polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003361 porogen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
肿瘤细胞 | 抑制率(%) |
肝癌肺癌食管癌胃癌乳腺癌胰腺癌甲状腺癌鼻咽癌卵巢癌子宫内膜癌子宫颈癌肾癌前列腺癌膀胱癌结肠癌直肠癌皮肤癌睾丸癌 | 929082888494928868808068708282808684 |
实施例十二 | 1天 | 3天 | 5天 | 7天 | 14天 |
(A) | 19 | 40 | 59 | 78 | 92 |
(B) | 20 | 39 | 61 | 78 | 88 |
(C) | 21 | 41 | 61 | 72 | 89 |
(D) | 21 | 42 | 61 | 81 | 89 |
(E) | 21 | 41 | 61 | 71 | 86 |
(F) | 23 | 39 | 60 | 79 | 92 |
(G) | 12 | 31 | 52 | 68 | 80 |
(H) | 13 | 32 | 48 | 72 | 81 |
(I) | 12 | 30 | 50 | 73 | 80 |
(J) | 11 | 31 | 49 | 70 | 78 |
实施例十二 | 1天 | 3天 | 5天 | 7天 | 14天 | 21天 | 28天 |
(A) | 10 | 27 | 33 | 50 | 72 | 92 | 95 |
(B) | 12 | 21 | 33 | 52 | 72 | 92 | 96 |
(C) | 11 | 22 | 33 | 51 | 73 | 91 | 95 |
(D) | 14 | 20 | 29 | 48 | 72 | 89 | 94 |
(E) | 12 | 23 | 26 | 49 | 69 | 88 | 89 |
(F) | 12 | 23 | 26 | 48 | 68 | 90 | 89 |
(G) | 6 | 15 | 20 | 36 | 62 | 78 | 85 |
(H) | 9 | 17 | 21 | 31 | 60 | 74 | 84 |
(I) | 8 | 15 | 19 | 33 | 58 | 76 | 86 |
(J) | 9 | 16 | 18 | 36 | 56 | 74 | 82 |
组别 | 剂量(mg/kg) | 动物数(只) | 给药途径次数 | 体重(x±s,g) | 瘤重(x±s.g) | 抑制率(%) | p值 | |
前 | 后 | |||||||
生理盐水组 | 10 | ip×1 | 19.61±1.15 | 21.775±1.1 | 5.4089±0.921 | - | ||
卡莫司汀腹腔组 | 21.768 | 10 | ip×1 | 19.84±2.0 | 21.057±1.6 | 3.669±0.728 | 32.14 | <0.001 |
卡莫司汀局部组 | 21.768 | 10 | ip×10 | 19.64±1.8 | 22.387±2.1 | 4.309±0.549 | 20.47 | =0.005 |
高聚组 | 0 | 10 | 瘤内植入 | 19.52±1.5 | 23.634±0.95 | 5.389±0.644 | 0.36 | >0.1 |
植入剂7.5%组 | 117.18 | 10 | 瘤内植入 | 19.42±1.2 | 22.089±1.5 | 4.738±0.834 | 12.37 | >0.1 |
植入剂15%组 | 234.37 | 10 | 瘤内植入 | 19.89±1.1 | 19.043±1.7 | 1.353±0.764 | 74.9 | <0.001 |
植入剂30%组 | 468.75 | 10 | 瘤内植入 | 19.11±1.7 | 16.803±1.7 | 0.458±0.266 | 91.5 | <0.001 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100434800A CN1330299C (zh) | 2005-05-13 | 2005-05-13 | 一种治疗颅外实体肿瘤的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100434800A CN1330299C (zh) | 2005-05-13 | 2005-05-13 | 一种治疗颅外实体肿瘤的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698592A CN1698592A (zh) | 2005-11-23 |
CN1330299C true CN1330299C (zh) | 2007-08-08 |
Family
ID=35474945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100434800A Expired - Fee Related CN1330299C (zh) | 2005-05-13 | 2005-05-13 | 一种治疗颅外实体肿瘤的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1330299C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523566A (zh) * | 2014-12-15 | 2015-04-22 | 山东蓝金生物工程有限公司 | 一种治疗实体肿瘤的卡莫司汀缓释植入剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403758B1 (en) * | 1997-08-18 | 2002-06-11 | Scimed Life Systems, Inc. | Bioresorbable compositions for implantable prostheses |
CN1524580A (zh) * | 2003-02-26 | 2004-09-01 | 天津市第一中心医院 | 卡氮芥缓释膜片及其制备方法 |
CN1687494A (zh) * | 2005-04-05 | 2005-10-26 | 中国科学院长春应用化学研究所 | 卡氮芥的超细纤维剂型的制备方法 |
-
2005
- 2005-05-13 CN CNB2005100434800A patent/CN1330299C/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403758B1 (en) * | 1997-08-18 | 2002-06-11 | Scimed Life Systems, Inc. | Bioresorbable compositions for implantable prostheses |
CN1524580A (zh) * | 2003-02-26 | 2004-09-01 | 天津市第一中心医院 | 卡氮芥缓释膜片及其制备方法 |
CN1687494A (zh) * | 2005-04-05 | 2005-10-26 | 中国科学院长春应用化学研究所 | 卡氮芥的超细纤维剂型的制备方法 |
Non-Patent Citations (1)
Title |
---|
生物胶卡氮芥混合剂局部缓释化疗治疗胶质瘤 李中民等,现代神经病杂志,第2卷第6期 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1698592A (zh) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101204365A (zh) | 一种治疗实体肿瘤的植入剂 | |
CN101219102A (zh) | 一种治疗实体肿瘤的拉帕替尼缓释植入剂 | |
CN1330299C (zh) | 一种治疗颅外实体肿瘤的药物组合物 | |
CN101176713B (zh) | 治疗实体肿瘤的卡莫司汀缓释植入剂 | |
CN100563644C (zh) | 一种治疗实体肿瘤的卡莫司汀缓释植入剂 | |
CN101219101A (zh) | 一种治疗实体肿瘤的氟达拉滨缓释植入剂 | |
CN101204367A (zh) | 一种治疗实体肿瘤的阿西替尼缓释植入剂 | |
CN1311817C (zh) | 一种治疗实体肿瘤的药物组合物 | |
CN101185629A (zh) | 一种治疗实体肿瘤的地西他滨缓释剂 | |
CN101224185A (zh) | 一种治疗实体肿瘤的伯舒替尼缓释植入剂 | |
CN101204369A (zh) | 一种治疗实体肿瘤的索非拉尼缓释植入剂 | |
CN1311818C (zh) | 一种抗实体肿瘤的药物组合物 | |
CN101204366A (zh) | 一种治疗实体肿瘤的美法仑缓释植入剂 | |
CN101181235B (zh) | 一种治疗实体肿瘤的坦度替尼缓释植入剂 | |
CN1311872C (zh) | 一种抗癌药物组合物 | |
CN101181234B (zh) | 一种治疗实体肿瘤的利特替尼缓释植入剂 | |
CN101181231B (zh) | 一种洛托替康缓释植入剂 | |
CN101176710A (zh) | 一种治疗实体肿瘤的米托蒽醌缓释植入剂 | |
CN100531712C (zh) | 一种治疗实体肿瘤的达萨替尼缓释植入剂 | |
CN101185632A (zh) | 一种治疗实体肿瘤的罗那法尼缓释植入剂 | |
CN101176712A (zh) | 一种治疗实体肿瘤的尼莫司汀缓释植入剂 | |
CN101204368A (zh) | 一种治疗实体肿瘤的吡柔比星缓释植入剂 | |
CN100586435C (zh) | 一种治疗实体肿瘤的卡莫氟缓释植入剂 | |
CN100531711C (zh) | 一种治疗实体肿瘤的埃罗替尼缓释植入剂 | |
CN101176716A (zh) | 一种治疗实体肿瘤的舒尼替尼缓释植入剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee after: Kong Qingzhong Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: 250100 No. 69, building 7, Pioneer Park, Huayang Road, Ji'nan hi tech Development Zone, Shandong, -802 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANDONG LANJIN BIOENGINEERING CO., LTD. Effective date: 20110315 Free format text: FORMER OWNER: KONG QINGZHONG |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE TO: 250101 ROOM 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110315 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee after: Shandong many biological pharmaceutical Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Co-patentee before: Kong Qingzhong Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: DASEN BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee after: DASEN BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Room 201 Patentee before: Shandong many biological pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070808 Termination date: 20170513 |